肺癌

日本的Kurata博士在Annals of Oncology报道：

　　一例70岁男性晚期肺腺癌患者,于1998年接受不含铂的化疗方案治疗达到稳定后进展，2000年3月开始服用易瑞沙700mg/日，有效18个月后进展，随后接受了含铂方案化疗，达到部分缓解。2002年8月又出现肿瘤进展，病人要求重新服用Iressa，遂予250 mg/日口服。一个月后，患者又出现肿瘤缓解。

    这个例子提示，至少在部分患者身上获得性的耐药是可以被克服的，并非所有的肿瘤细胞都会一直对某种用过的药物耐药。在这个病人身上，由于病人出现进展后又再次用化疗，而且化疗达到了部分缓解，提示有可能原来耐药的肿瘤细胞可能已被化疗杀灭，而在化疗过程中出现增殖的对化疗耐药的肿瘤细胞却又对Iressa敏感，此时再次使用Iressa又显示出了疗效。

    显然，这种获得性耐药的情况的克服是有条件的，细胞毒性化疗药物的价值在该病例中仍然得以体现。

看过此文章的朋友还看过
易瑞沙耐药后的治疗方法    特罗凯(Tarceva)中文说明书

有意团购印度易瑞沙 印度特罗凯 印度力比泰 请加入我们的群
官方QQ群1：26438631  官方QQ群2：5100806  或QQ 3 5 7 6 8 7 5 注明

====  汉译英 ====

Dr. Kurata of Japan reported in the Annals of Oncology:

Case of 70 year-old male patient with advanced lung cancer in 1998 received chemotherapy in the treatment of non-platinum to achieve stable progress in March 2000 began taking Iressa 700mg / day, effective after 18 months of progress, and then accepted the platinum program chemotherapy to achieve partial remission. In August 2002 appeared to tumor progression, patients require re-taking Iressa, subsequently to 250 mg / day orally. A month later, the patient appeared to alleviate tumor.

     This example prompts, at least in some patients with acquired drug resistance can be overcome, not all tumor cells would have been used for some kind of drug resistance. In this patient, due to progress of the patient then re-emerged with chemotherapy, and chemotherapy achieved partial remission, suggesting that there may be the original tumor cells resistant to chemotherapy may have been to kill, and in the proliferation occurred during chemotherapy to chemotherapy resistance tumor cells but on the Iressa-sensitive, this time again using Iressa has shown efficacy.

     Obviously, this was the case of overcoming drug resistance is conditional, the value of cytotoxic chemotherapy in the case is still to be reflected.